Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy

被引:57
|
作者
Munir, WM
Pulido, JS
Sharma, MC
Buerk, BM
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Univ Illinois, Chicago Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL USA
来源
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE | 2005年 / 40卷 / 05期
关键词
intravitreal steroids; pars plana vitrectomy; proliferative diabetic retinopathy; proliferative vitreoretinopathy; triamcinolone acetonide;
D O I
10.1016/S0008-4182(05)80052-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: We present a retrospective evaluation of the clinical outcome and complications associated with intravitreal injection of unaltered triamcinolone acetonide in conjunction with pars plana vitrectomy and silicone oil injection for the treatment of complicated proliferative diabetic retinopathy with tractional retinal detachment and severe proliferative vitreoretinopathy. Methods: Thirteen eyes of 12 consecutive patients were identified from a computerized patient database. All eyes were operated on by the same surgeon and received 4 mg of unaltered, commercially available triamcinolone acetonide intravitreally, before silicone oil injection. The patients were followed for a mean of 4.7 months (range 1-15 months), and demographic as well as pertinent preoperative and postoperative clinical information was gathered. Results: At the last follow-up visit, vision had improved in 4 eyes, remained stable in 5 eyes, and worsened in 4 eyes. The retina was attached at the end of follow-up in 10 of the 13 eyes. Eight of the 13 eyes did not show any clinical signs of reproliferation or redetachment during the course of follow-up. The mean intraocular pressure did not increase (preoperative value was 10.8 6.22 mm Hg with a range of 0-22 mm Hg; at last follow-up, mean pressure was 9.6 +/- 3.86 mm Hg with a cumulative postoperative range of 0-26 mm Hg). Steroid crystals were visible at 1 month postoperatively in 3 eyes and did not hinder fundus examination significantly. Interpretation: The intravitreal injection of low-dose, unaltered triamcinolone acetonide in the setting of pars plana vitrectomy and silicone oil injection for the treatment of proliferative vitreoretinopathy and complicated proliferative diabetic retinopathy appears to be well tolerated. Further controlled study is needed to clearly define the potential beneficial effects of intravitreal steroids in these 2 disease processes.
引用
收藏
页码:598 / 604
页数:7
相关论文
共 50 条
  • [31] Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation
    Cao, Guofan
    Xu, Xiangzhong
    Wang, Chenghu
    Zhang, Shu
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2020, 30 (01) : 34 - 39
  • [32] Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy
    El-Batarny, Ashraf M.
    CLINICAL OPHTHALMOLOGY, 2007, 1 (02): : 149 - 155
  • [33] Endoscopic vitreoretinal surgery for complicated proliferative diabetic retinopathy
    Ciardella, AP
    Fisher, YL
    Carvalho, C
    Slakter, JS
    Bryan, RG
    Sorenson, JA
    Spaide, RF
    Freund, KB
    Guyer, DR
    Yannuzzi, LA
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2001, 21 (01): : 20 - 27
  • [34] Proliferative vitreoretinopathy: Curative treatment
    Chiquet, C.
    Rouberol, F.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2014, 37 (08): : 653 - 659
  • [35] Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy
    Cui, Jinglin
    Chen, Hong
    Lu, Hang
    Dong, Fangtian
    Wei, Dongmei
    Jiao, Yan
    Charles, Steve
    Gu, Weikuan
    Wang, Lin
    JOURNAL OF OPHTHALMOLOGY, 2018, 2018
  • [36] Personalized Management of Patients with Proliferative Diabetic Vitreoretinopathy
    Ecsedy, Monika
    Szabo, Dorottya
    Szilagyi, Zsuzsa
    Nagy, Zoltan Zsolt
    Recsan, Zsuzsanna
    LIFE-BASEL, 2024, 14 (08):
  • [37] Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy
    Modarres, Mehdi
    Nazari, Hossein
    Falavarjani, Khalil Ghasemi
    Naseripour, Masood
    Hashemi, Masih
    Parvaresh, Mohammad Mehdi
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2009, 19 (05) : 848 - 852
  • [38] Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide
    Jonas, JB
    Kreissig, I
    Degenring, RF
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2003, 220 (06) : 384 - 390
  • [39] INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY
    Su, Long
    Ren, Xinjun
    Wei, Huiyu
    Zhao, Li
    Zhang, Xiaomin
    Liu, Juping
    Su, Chang
    Tan, Liangzhang
    Li, Xiaorong
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (05): : 938 - 943
  • [40] Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy
    Ren, Xinjun
    Bu, Shaochong
    Zhang, Xiaomin
    Jiang, Yuanfeng
    Tan, Liangzhang
    Zhang, Hong
    Li, Xiaorong
    EYE, 2019, 33 (07) : 1177 - 1183